WELCOME TO SANARIA

Sanaria is a biotechnology company dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Sanaria’s vaccine is based on an approach to immunization that has already proven highly protective in humans.
Learn more

Plasmodium falciparum malaria is responsible for more childhood mortality than any other single infectious agent. Sanaria’s vaccine development efforts are focused on African children, the population most urgently in need of protection. Annually, malaria is responsible for more than 100 million cases and 1 million deaths among African infants and children. Globally there are additional unmet medical needs of enormous proportions, and multiple potential markets.
Learn more

Sanaria is a Maryland-based company that is continually seeking motivated staff and investors with a passion to engage in the fight against malaria.
Learn more

Sanaria hosted Maryland 6th District United States Congressman John Delaney. Representative Delaney toured Sanaria's facilities and received an overview of Sanaria's Clinical Development Program. (L to R) Rep. Delaney, Dr. B Kim Lee Sim and Dr. Stephen L Hoffman.

Sanaria participates in Rally for Medical Research to raise awareness of the critical need to make funding for the National Institutes of Health (NIH) a national priority, April, 2013.

Learn more

Science publishes Sanaria's Research Article, Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity

Sanaria Press Release

Background

FAQs

Author Bios

Navy Press Release

NIH/NIAID Press Release

UMB Press Release

Sanaria and Alexandria Real Estate Equities hosted Dr. Francis S. Collins, Director of the National Institutes of Health, at the Tech Council of Maryland's BioBoardroom session on April 27, 2011. Dr. Collins spoke on what the new National Center for Advancing Translational Sciences will mean to Maryland biotechnology companies. Dr. Stephen Hoffman and Sanaria staff members, Yeab Getachew, Claire Wernly and Gwynne Roth (L to R) were pleased to have Dr. Collins sign their copies of his book, 'The Language of God: A Scientist Presents Evidence for Belief.'

Sanaria ranked 15th among all Maryland businesses in The Gazette of Politics and Business Exceptional 53 Business Awards, September, 2010.

Photo courtesy of the Gazette of Politics and Business, Anthony Castellano.

Learn more

Sanaria attends WHO's Scientific Forum on Malaria Vaccine: Progress and Challenges in Development of Whole Organism Malaria Vaccine for Endemic Countries. Dakar, Senegal, Africa, June, 2009.

Sanaria wins Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech at the 2009 World Vaccine Congress Washington.

Learn more

Sanaria team retreat.

Learn more

Sanaria named Emerging Company of the Year at the annual Technology Council of Maryland's Tech Awards Celebration.

Learn more

Home of Sanaria's headquarters in Rockville, Maryland.

Learn more

If you are interested in information about enrollment or participation in Sanaria's clinical trials, please contact us.

March 2013
Sanaria's CEO & CSO, Dr. Stephen L. Hoffman, ranked 21st out of the 50 most influential people in vaccines; 50 most influential

January 2013
In collaboration with the Radboud University Nijmegen Medical Center, a high level of controlled human malaria infection (CHMI) was achieved with Sanaria^® PfSPZ Challenge paving the way towards the elimination of the need for live mosquito bites to test anti-malarial vaccines and drugs; AJTMH, Healio

January 2013
Sanaria Sr. Director, Dr. Eric James, publishes in Vaccine; Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine

January 2013
Dr. Judith E. Epstein publishes in AJTMH; Taking a Bite out of Malaria: Controlled Human Malaria Infection by Needle and Syringe

January 2013
Sanaria featured in the BBC's news story, A Faster Path to a Possible Malaria Vaccine

October 2012
Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2012

June 2012
Sanaria and the Institute for Bioscience and Biotechnology Research of the University of Maryland College Park Awarded Collaborative, US $3M NIH Phase II Small Business Innovation Research Grant; Press Release

January 2012
The Sanaria^®PfSPZ Vaccine is being assessed in a clinical trial at the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health (Press Release). The VRC investigators are recruiting additional volunteers for the study (contact NIAID here and ask to participate in the Sanaria^®PfSPZ Vaccine study)

October 2011
Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2011

September 2011
Science publishes Sanaria's Research Article, Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity,; Sanaria Press Release, Background, FAQs, Author Bios, Navy Press Release, NIH/NIAID Press Release, UMB Press Release

June 2011
Sanaria announces the launch of its Sanaria^® Family of Products and Services intended to advance research towards new malaria vaccines, drugs, and diagnostics, and enhanced understanding of malaria pathology and immunobiology; Press Release

April 2011
Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, were nominated as one of the Tech Council of Maryland's three finalists for the 2011 Tech Awards for Biotechnology Firm of the Year and Executive of the Year, respectively

March 2011
Sanaria is proud to announce the appointment of Peter F. Billingsley, PhD, Senior Director of Entomology and Quality Systems, to the Editorial Board of the Malaria Journal; more information

Older News